Covid-19 roundup: No­vavax's man­u­fac­tur­ing woes near­ing an end?; FDA re­jects coro­n­avirus drug in NIH tri­al

The US gov­ern­ment’s $1.8 bil­lion in­vest­ment in­to No­vavax’s Covid-19 vac­cine may soon pay off as the com­pa­ny float­ed some pos­i­tive com­ments around the is­sues sur­round­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER